|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Omeros Corporation
| | | Phone: | (206) 676-5000 | Fax: | (206) 676-5005 | Year Established: | 1994 | Employees: | 75 | Ticker: | OMER | Exchange: | NASDAQ | Main Contact: | Gregory A. Demopulos, M.D., Chairman & CEO | | Other Contacts: | William J. Lambert, Ph.D., VP, Chemistry, Manufacturing and Controls Christopher S. Bral, Ph.D., VP, Nonclinical Development Leonard M. Blum, Chief Business & Commercial Officer Eckhard Leifke, M.D., CMO & VP of Clinical Development Michael A. Jacobsen, Chief Accounting Officer Timothy M. Duffy, VP, Business Development George A Gaitanaris, M.D., Ph.D., CSO Marcia S. Kelbon, Esq., General Counsel
and Secretary Cathy Melfi, Ph.D., Chief Regulatory Officer
| | Company Description | Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the company’s first drug product, OMIDRIA® (phenylephrine and ketorolac injection) 1%/0.3%, was broadly launched in the U.S. in April 2015 for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. In the European Union, the European Commission has approved OMIDRIA for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; complement-mediated glomerulopathies; Huntington’s disease and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development, and a platform used to generate antibodies. | |
|
|
|
|
|